16 completed. 16 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 5 | Completed 5 |
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers BI 905711, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Metastatic | Phase 1 | Completed | Boehringer Ingelheim | 13 | 2021-11-24 | 2025-02-19 |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Gevokizumab, Bevacizumab, Modified FOLFOX6 - Colorectal Cancer, Gastroesophageal Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 167 | 2019-05-22 | 2026-04-01 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer ompenaclid, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 1 | Completed | Inspirna, Inc. | 89 | 2018-06-05 | 2025-04-03 |
| A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy irinotecan, FOLFIRI - Metastatic Colorectal Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Green Cross Corporation | 53 | 2018-04-02 | 2022-03-03 |
| Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors TSR-033, Dostarlimab, mFOLFOX6 - Neoplasms | Phase 1 | Completed | Tesaro, Inc. | 111 | 2017-08-08 | 2024-04-11 |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies ABBV-621, Venetoclax, Bevacizumab - Advanced Solid Tumors, Cancer | Phase 1 | Completed | AbbVie | 153 | 2017-03-20 | 2022-12-09 |
| A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 OMP-131R10, FOLFIRI - Advanced Relapsed Tumors, Refractory Solid Tumors | Phase 1 | Completed | OncoMed Pharmaceuticals, Inc. | 50 | 2015-07-16 | 2020-08-11 |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors Veliparib, Carboplatin, Paclitaxel - Breast Cancer, Ovarian Cancer | Phase 1 | Completed | AbbVie | 47 | 2013-12-01 | 2016-09-27 |
| A Study of ABT-165 in Subjects With Solid Tumors paclitaxel, FOLFIRI, ABT-165 - Advanced Solid Tumors | Phase 1 | Completed | AbbVie | 101 | 2013-08-08 | 2023-12-15 |
| Study of ABT-700 in Subjects With Advanced Solid Tumors ABT-700, docetaxel, FOLFIRI - Advanced Solid Tumors | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 74 | 2011-10-06 | 2017-11-21 |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma 4SC-201(Resminostat), FOLFIRI - Advanced Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | 4SC AG | 17 | 2011-01-01 | 2015-04-01 |
| Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments CS-1008, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 | Completed | Daiichi Sankyo | 21 | 2010-05-01 | 2013-12-03 |
| Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) Cetuximab, FOLFIRI, FOLFOX - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 289 | 2009-02-01 | 2015-05-14 |
| Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer FOLFOX-4, AMG 706, Panitumumab (Part 1a only) - Rectal Cancer, Colon Cancer | Phase 1 | Completed | Amgen | 119 | 2004-12-01 | 2012-09-17 |
Colorectal Neoplasms (12) · Neoplasms (4) · Colonic Neoplasms (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1)
AbbVie (3) · 4SC AG (1) · AbbVie (prior sponsor, Abbott) (1) · Amgen (1) · Boehringer Ingelheim (1) · Cardiff Oncology (1) · Daiichi Sankyo (1) · Green Cross Corporation (1) · Inspirna, Inc. (1) · Karyopharm Therapeutics Inc (1) · Merck KGaA, Darmstadt, Germany (1) · Novartis Pharmaceuticals (1) · OncoMed Pharmaceuticals, Inc. (1) · Tesaro, Inc. (1)
United States (10) · Japan (3) · Spain (3) · Belgium (2) · France (2) · Germany (2) · Israel (2) · Netherlands (2) · Singapore (2) · South Korea (2) · Australia (1) · Canada (1) · Chile (1) · China (1) · Czechia (1)
Louie Naumovski, MD (1) · Robert Wasserman, MD (1) · Stacie Shepherd, PhD (1) · Yung Jue Bang, M.D.,Ph.D. (1)
PMID 25772756, PMID 34315767, PMID 34646387, PMID 35467243, PMID 36720090, PMID 38036720, PMID 38231047, PMID 39475591, PMID 40016550
2016 (1), 2018 (1)